Zacks: Brokerages Expect Xenon Pharmaceuticals Inc (NASDAQ:XENE) to Post -$0.49 EPS

Share on StockTwits

Brokerages expect that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will report ($0.49) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Xenon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.52) and the highest is ($0.45). Xenon Pharmaceuticals reported earnings per share of ($0.29) in the same quarter last year, which would suggest a negative year-over-year growth rate of 69%. The firm is expected to announce its next earnings report on Wednesday, March 4th.

On average, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.66) per share for the current fiscal year, with EPS estimates ranging from ($1.69) to ($1.63). For the next year, analysts forecast that the firm will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.02) to ($1.83). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Xenon Pharmaceuticals.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.16. The company had revenue of $3.50 million during the quarter.

XENE has been the subject of a number of recent research reports. ValuEngine lowered Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Zacks Investment Research raised Xenon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price on the stock in a report on Saturday, October 26th. BidaskClub raised Xenon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 5th. Finally, Guggenheim started coverage on Xenon Pharmaceuticals in a report on Friday, September 20th. They issued a “buy” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $17.67.

NASDAQ:XENE traded down $0.71 on Friday, hitting $13.28. 90,318 shares of the stock were exchanged, compared to its average volume of 205,769. The stock has a market cap of $345.61 million, a PE ratio of -9.98 and a beta of 1.44. The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average of $10.44 and a 200-day moving average of $9.66. Xenon Pharmaceuticals has a fifty-two week low of $5.41 and a fifty-two week high of $14.95.

In other news, Director Frank A. Holler sold 7,600 shares of Xenon Pharmaceuticals stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $9.27, for a total value of $70,452.00. Following the transaction, the director now directly owns 124,161 shares in the company, valued at $1,150,972.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Simon N. Pimstone sold 10,395 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $9.51, for a total value of $98,856.45. Following the completion of the transaction, the chief executive officer now owns 258,122 shares in the company, valued at $2,454,740.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,064 shares of company stock valued at $216,552. Insiders own 8.35% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asset Management L.P. boosted its holdings in shares of Xenon Pharmaceuticals by 8.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 925,000 shares of the biopharmaceutical company’s stock worth $9,121,000 after acquiring an additional 75,000 shares in the last quarter. Northern Trust Corp increased its position in shares of Xenon Pharmaceuticals by 55.5% in the 2nd quarter. Northern Trust Corp now owns 37,636 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 13,434 shares in the last quarter. NEA Management Company LLC bought a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $1,802,000. Supplemental Annuity Collective Trust of NJ bought a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $99,000. Finally, Granahan Investment Management Inc. MA increased its holdings in Xenon Pharmaceuticals by 8.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 106,459 shares of the biopharmaceutical company’s stock worth $959,000 after purchasing an additional 8,200 shares in the last quarter. Hedge funds and other institutional investors own 67.68% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Read More: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.